The mu opioid receptor is involved in many natural processes including stress response, pleasure, and pain. Mutations in the gene also have been associated with opiate and alcohol addictions as well as with responsivity to medication targeting these disorders. Two common and mutually exclusive polymorphisms have been identified in humans, A118G (N40D), found commonly in non-African populations, and C17T (V6A), found almost exclusively in African populations. Although A118G has been studied extensively for associations and in functional assays, C17T is much less well understood. In addition to a parallel polymorphism previously identified in rhesus macaques (Macaca mulatta), C77G (P26R), resequencing in additional non-human primate species identifies further common variation: C140T (P47L) in cynomolgus macaques (Macaca fascicularis), G55C (D19H) in vervet monkeys (Chlorocebus aethiops sabeus), A111T (L37F) in marmosets (Callithrix jacchus), and C55T (P19S) in squirrel monkeys (Saimiri boliviensis peruviensis). -ol]-enkephalin), and fentanyl. In addition to demonstrating the importance of functional equivalency in reference to population variation for minority health, this also shows how common evolutionary pressures have produced similar phenotypes across species, suggesting a shared response to environmental needs and perhaps elucidating the mechanism by which these organismenvironment interactions are mediated physiologically and molecularly. These studies set the stage for future investigations of shared functional polymorphisms across species as a new genetic tool for translational research.
Introduction
The endogenous opioid system is central to a number of natural behaviors, most notably as a mediator of reward via the mesolimbic circuitry (Le Merrer et al. 2009; Navratilova and Porreca 2014; Fields and Margolis 2015) . The mu opioid receptor, in particular, is central to these actions (Kieffer 1999; Contet et al. 2004; Le Merrer et al. 2009 ). Representing such a basal behavior and expressed in such ancient neuroanatomical structures, this system is evolutionarily strongly conserved extending back at least to the last common ancestor of euteleostomes (Dreborg et al. 2008; McClendon et al. 2010) . Likely exploiting conserved physiological functions for defense (Wink 2000 (Wink , 2003 , the opium poppy (Papaver somniferum) produces the mu receptor agonists morphine and codeine (Ziegler et al. 2009 ). Humans, since ancient times, have medicinally and recreationally used the poppy plant for its painrelieving effects and subsequent addictive qualities (Brownstein 1993) . It was through these roles that human genetic variation in the mu opioid receptor first became apparent (Bergen et al. 1997; Bond et al. 1998) .
The most commonly studied human variation in the mu opioid receptor (summarized in fig. 1 ) is the A118G (N40D) polymorphism, with minor allele frequencies (MAFs) ranging between 10% and 50% in populations outside of Africa (Gelernter et al. 1999; Lopez Soto and Catanesi 2015) . A number of studies associating the A118G polymorphism with a variety of phenotypes have been published. Perhaps most notably this polymorphism has been associated with alcoholism (Kranzler et al. 1998; Smolka et al. 1999; Town et al. 1999; Rommelspacher et al. 2001; Oslin et al. 2003; Ray and Hutchison 2004; Bart et al. 2005; Nishizawa et al. 2006; Zhang et al. 2006; van den Wildenberg et al. 2007; Filbey et al. 2008 ) and opiate addiction (Bond et al. 1998; Szeto et al. 2001; Shi et al. 2002; Zhang et al. 2007; Haerian and Haerian 2013) , but there also have been associations with more general non-disease phenotypes (e.g. stress response [Hernandez-Avila et al. 2003 ], novelty-seeking [Rommelspacher et al. 2001 ] and affiliative behavior [Troisi et al. 2011] ). Of course, an association with a disease holds with it numerous caveats (Lotsch and Geisslinger 2005) . The polymorphism may be a marker in linkage disequilibrium with the actual functional variant and, in human studies in particular, rather than an exception this may be the norm. In addition, despite the best efforts of researchers, false positives abound and, indeed, there are many studies failing to find an association between A118G and the same phenotypes (Arias et al. 2006; Gelernter et al. 2007; Coller et al. 2009 ).
Biologically, as well as sociologically, it is also worth remarking on a second variant, C17T (A6V). This variant is almost absent in populations outside of Africa, but is relatively common in African populations surveyed. (Here we use 'African' as a colloquial shorthand but at present this is largely representative of populations from the NigerKordofanian language family of West and Central Africa, and may or may not be more broadly applicable.) There are relatively few studies that focus on this polymorphism, especially compared with its outside-of-Africa A118G counterpart. It is worth noting, however, that what few publications there are also seem to show similar patterns of association (Hoehe et al. 2000; Rommelspacher et al. 2001; Crowley et al. 2003; Kapur et al. 2007; Crystal et al. 2012 ). This provides further suggestive evidence that these polymorphisms are indeed functionally relevant.
Concerns regarding the actual functional effects of the variants are ameliorated in part by independent replication across studies and populations, but also by our understandings of the basic biology of the system, in this case the protein structure and ligand interactions (Manglik et al. 2012; Cui et al. 2013) , and the role of the protein from a neurobiological systems perspective (Barish et al. 2013; Kaufman et al. 2013; Ray et al. 2014 ). In the case of the mu opioid receptor, we also are aided by the fact that we can recapitulate the associations in animal models. The association between A118G and alcoholism in humans is paralleled by similar associations between C77G and alcohol drinking behaviors in rhesus macaques (Barr et al. 2007; Vallender et al. 2010) as is the pharmacogenetic responsivity to naltrexone Vallender et al. 2010) , stress response (Miller et al. 2004; Schwandt et al. 2011 ) and affiliative behavior (Barr et al. 2008; Higham et al. 2011) . As another confirmation of functional importance of the variation, humanized mice carrying the two variants have been developed that show differential response to alcohol (Ramchandani et al. 2011; Bilbao et al. 2015) , morphine (Mague et al. 2009; Mahmoud et al. 2011; Robinson et al. 2015; Henderson-Redmond et al. 2016) , and stress response (Briand et al. 2015) .
Finally, there is a growing literature of in vitro functional studies of second messenger signaling that shows evidence for differential ligand binding and signaling for polymorphisms in the mu-opioid receptor. In the human literature, there is significant variation due, in part, to differences in methodologies that may not reflect similar underlying biological mechanisms (reviewed in . As with the association studies, the majority of in vitro work have focused on A118G. Several studies have shown significant differences between the variants though they do not agree on which variant has greater potency for morphine or DAMGO ( -ol]-enkephalin), A118 (Kroslak et al. 2007; Mahmoud et al. 2011) or G118 (Bond et al. 1998; Margas et al. 2007; Lopez Soto and Raingo 2012) , while other studies find no difference at all (Beyer et al. 2004; Fortin et al. 2010; Ramchandani et al. 2011; Knapman et al. 2014) . Although the work on C17T is less plentiful, a similar disparity of results is observed with some studies showing no effect (Fortin et al. 2010 ) and others showing significant results . Although our own previous results with the rhesus macaque C77G polymorphism finds an effect (Miller et al. 2004) , it has remained unconfirmed.
As outlined earlier, existing literature has described three independent events of seemingly functional common variation arising in the mu-opioid receptor: A118G in "Out-ofAfrica" human populations, C17T in African human ECL1  ECL2  ECL3   ICL1  ICL2  ICL3   TM1  TM2  TM3  TM4  TM5  TM6  TM7   49992 bp  774 bp  27211 MBE populations, and C77G in rhesus macaques. This has begun to raise the question of the evolutionary origins of this variation. It is possible that this simply represents a relatively recent and pervasive relaxation of constraint on the receptor or that this is simply a coincidental byproduct of demography. The long conservation of the receptor, recurring nature of the variation, and the high MAFs of the polymorphisms, however, suggests that there may be additional biological meaning behind the patterns observed. Here, the mu opioid receptor (OPRM1) is broadly surveyed for genetic variation across several primate species. The nature and distribution of this variation is then compared for evidence of selection. Finally, in vitro studies are performed which confirm that the observed variation is functionally relevant.
Results

Human Coding Polymorphism in OPRM1
Human variation in the mu-opioid receptor is well established. The A118G (N40D; rs1799971) polymorphism is particularly common outside of Africa while the C17T (A6V; rs1799972) polymorphism is more common in Africa; neither is commonly observed where the other predominates. This Africa/Out-of-Africa dichotomy can be seen for A118G in the Human Genome Diversity Project (Li et al. 2008 ) which broadly sampled populations (supplementary fig. S1 , Supplementary Material online) or in the 1000 Genomes Project (Sudmant et al. 2015) where MAFs in African subpopulations (0%-1%, 5% in African-Americans) are significantly less than those in European subpopulations (11%-18%), American subpopulations (16%-20%), or East Asian subpopulations (33%-50%). Similar frequencies were also found in Phase III of the HapMap project (The International HapMap 3 Consortium 2010) (table 1) . Unfortunately, there is a dearth of data on C17T. It was not included in the SNP panel used for the HGDP and, while it was identified in the initial phases of the HapMap project (Frazer et al. 2007) , it was unclear to what degree the Yoruba population frequencies (MAF: 28.3%) could be extrapolated to the rest of sub-Saharan Africa. These early HapMap studies showed little, if any, presence in European or East Asian Sharad et al. 2007 ). With the 1000 Genomes Project (Sudmant et al. 2015) and expanded testing of diverse populations, the commonality of C17T across Africa and absence outside of Africa was confirmed; five South Asian populations had MAF < 1% (Table 1) . Additional populations from sub-Saharan Africa likewise show common MAFs, ranging from 17.6% in the Mende of Sierra Leone to 34.3% in the Esan of Nigeria. It is perhaps notable that all the African populations in which C17T has been commonly identified, and indeed in which it has been broadly investigated, share a common language family, NigerKordofanian, and genetic ancestry in Western/Central Africa (Tishkoff et al. 2009 ). The Maasai population for Kinyawa, Kenya has been the only Nilo-Saharan population surveyed and it only for the A118G polymorphism. Notably, however, the MAF for A118G in this population is 3.2%, the highest observed in Africa and consistent with a monophyletic grouping with Out-of-Africa populations. Multiple studies find African-American (or Afro-Caribbean) populations with intermediate frequencies of C17T, in accordance with studies previous studies of genetic ancestry (Tishkoff et al. 2009; Zakharia et al. 2009 ).
Besides these two missense polymorphisms, there is one additional synonymous human variant that is relatively common, G942A (T314T; rs1799975). Again this variant is found exclusively in Africans (read: Western/Central African) and at low, but still common, MAFs (3%-6%; table 1). It appears to be effectively absent outside of Africa. Data from the 1000 Genomes Project (Sudmant et al. 2015) identifies an additional 16 polymorphisms (table 2), though none exceeds 1% MAF in the African, Asian, or European subpopulations.
Non-Human Primate Coding Polymorphism in OPRM1
In the rhesus macaque, OPRM1 variation has been well studied in populations of Indian origin (Miller et al. 2004; Vallender et al. 2008) . The variant receiving the most attention, C77G (P26R), is common with a MAF ranging between 15% and 30% at various Primate Research Centers (data not shown). Two additional common polymorphisms in Indian origin rhesus have been identified: one a conservative missense mutation, G86C (G29A), and one synonymous, G1314A. Although rhesus macaques used in academic research in the United States are overwhelmingly of Indian origin, Chinese origin rhesus macaques are increasingly becoming more commonly used in biomedical research, especially worldwide. Following resequencing of 40 Chinese origin rhesus macaques, three novel synonymous polymorphisms were identified though none of the Indian origin rhesus macaque polymorphisms, including C77G, were observed (table 3) . No polymorphisms that alter the amino acid sequence were identified outside of the N-terminal region.
The rhesus macaque variation in OPRM1 has shown striking similarities to human variation both in terms of in vitro functional effects (Miller et al. 2004; Vallender et al. 2008 )andinvivo phenotypes (Miller et al. 2004; Barr et al. 2007 Barr et al. , 2008 Barr et al. , 2010 Schwandt et al. 2010 Schwandt et al. , 2011 Vallender et al. 2010) . What is unclear is whether this is coincidental, uniquely due to generalist similarities between the two species, or if it represents a broader pattern. To explore this possibility, the OPRM1 gene was resequenced in a variety of other commonly used non-human primate species: Mauritian cynomolgus macaques (Macaca 
peruviensis).
Single nucleotide polymorphisms were identified in each species studied (table 3) including common missense mutations in Mauritian cynomolgus macaque, C140T (P47L), MAF: 25.7%; vervet monkey, G55C (D19H), MAF: 21.4%; and marmoset, A111T (L37F), MAF: 31.7%. Two missense mutations are observed in the Bolivian, G338A (R113K), and Peruvian squirrel monkey, C55T (P19S); though, particularly with the latter, small sample sizes make it difficult to infer true MAFs. Two factors are immediately striking about the nonsynonymous polymorphisms identified. First, largely, they are very common regardless of the species. Second, all but the Bolivian squirrel monkey SNP (perhaps not coincidentally also the one with the lowest MAF), are located in the Nterminal extracellular domain of the mu-opioid receptor protein. Interestingly, neither of these applied to synonymous changes. These changes that did not alter protein sequence were found to be evenly distributed throughout the length of the coding sequence and at frequencies in accordance with neutral expectation.
Comparative and Evolutionary Study of Polymorphism and Divergence
To test whether the apparent excess of common polymorphisms in the N-terminal domain was significant, the polymorphisms and fixed mutations between the six species under study were mapped onto the tertiary structure of the protein ( fig. 2 ). For these studies, the N-terminal domain of the protein was considered compared with the remainder of the protein.
A McDonald-Kreitman test (McDonald and Kreitman 1991) was used to compare divergence and polymorphism on synonymous and non-synonymous sites, including only polymorphisms with MAFs >5% in order to minimize the effects of slightly deleterious mutations destined for elimination (Charlesworth and Eyre-Walker 2008) . For the gene as a whole, the test does not find significant departures from neutral expectation (P ¼ 0.158, two-tailed Fisher Exact test). When divided based on the structural information, the N-terminal region is significant (P ¼ 0.039, two-tailed Fisher Exact test) while the rest of the protein is not (P ¼ 0.673, two-tailed Fisher Exact test). It is also important to note the direction of the deviations. In the N-terminal domain, there is an excess of non-synonymous polymorphisms compared with expectations from fixed divergence, while in the remainder of the protein the excess is in synonymous polymorphisms.
A log-linear analysis using a 2 Â 2 Â 2 contingency table separating the two regions confirmed the observation. The interaction between mutation function (synonymous/nonsynonymous) * lineage (divergence/polymorphism) * location In both cases, this is driven by an excess of non-synonymous polymorphisms specifically in the N-terminal domain.
Convergent Balancing
Another approach compared exon 1 to the remainder of the gene. Exon 1 encodes the N-terminal domain, the first transmembrane domain, and part of the first intracellular domain. In each of the six species under study it is separated from exon 2 by roughly 50 kb, allowing for more recombination and a greater assurance of linkage independence between the regions under study (though it should be noted that there does not appear to be any linkage disequilibrium among polymorphisms identified here). Nevertheless, this alternative approach, comparing exon 1 to exons 2-4, results in the same conclusions as comparing the N-terminal domain by itself to the remainder of the protein (data not shown).
Functional Relevance of Polymorphism
Although there seems to be an excess of nonsynonymous variation in the N-terminal region of the mu-opioid receptor in primates it is far from certain that this has any functional relevance; a reasonable null hypothesis could posit a relaxation of constraint. There are several lines of evidence, however that argue against this. First, as described earlier, there is an overall conservation between species in the same region. The relaxation of constraint would therefore need to be recent and pervasive across species. Because of the high MAFs of the polymorphisms it is unlikely that they simply represent slightly deleterious mutations destined to be eliminated. There are many statistical arguments suggesting that these polymorphisms are functionally meaningful, yet they are far from unambiguous.
A second line of evidence comes from the association studies, most notably in humans though also to a lesser degree in rhesus macaques. There are a large number of studies that have implicated either the mu-opioid receptor generally or the N-terminal polymorphisms in particular with diseases and behaviors. Of course, an association with a disease holds with it numerous caveats. The polymorphism may be a marker in linkage disequilibrium with the actual functional variant and, in human studies in particular, rather than an exception, linkage disequilibrium may be the norm. Also, despite the best efforts of researchers, human genetic associations remain fickle with false positives and false negatives abounding due to variability in study populations, environmental effects, and even variability in the way that the dependent variables are assessed. These concerns are ameliorated in part by independent replication across studies and populations, but also by our understandings of the basic biology of the system and our ability to recapitulate the associations in animal models.
In vitro studies allow for much greater levels of control and can more easily be used to address the specific effects of polymorphisms in the absence of confounding factors. Care still must be taken to ensure that in vitro conditions mimic those observed in vivo, but these studies can be a useful tool to confirm and expand upon organismal studies. Polymorphisms in the N-terminal domain are hypothesized to possibly have effects on ligand binding. Indeed, existing in vitro functional studies have previously shown evidence for differential ligand binding and signaling both for the human A118G polymorphism (Bond et al. 1998 ) and the rhesus macaque C77G polymorphism (Miller et al. 2004 ). These in vitro functional differences between the alleles lend additional credence to the association and evolutionary studies. To confirm and extend these results, we sought to test the human and non-human primate variants in parallel across a number of known ligands.
To test the effects of polymorphism on mu-opioid receptor function each of nine variants of interest (human: C17/ A118, C17/G118, T17/A118; rhesus macaque: C77, G77; marmoset: A111, T111; squirrel monkey: C55, T55), OPRM1 from each species were first cloned into a common standard expression vector and variants were introduced using sitedirected mutagenesis. These species were chosen because cDNA was readily available. Because there were no other polymorphisms that changed amino acid sequence on the same haplotype, this allowed the proteins expressed from each plasmid to be identical to those naturally occurring among individuals from the respective species. Clones were then transfected into an HEK293 cell line previously transduced with an inducible CRE-responsive firefly luciferase reporter lentivirus. Stable cell lines were then generated for each variant under study. In each experiment, cells were treated with forskolin and various concentrations of agonist for 20 h, lysed, and luminescence was read. Each experiment contained three technical replicates and positive controls consisting only of forskolin and negative controls consisting of an empty, non-OPRM1 containing plasmid also were run.
Four different agonists were used in the assay: b-endorphin, the endogenous ligand; morphine, a naturally-occurring opiate analgesic and drug of abuse; fentanyl, a synthetic opiate analgesic and drug of abuse; and DAMGO, a synthetic opiate peptide. These agonists were chosen because each has previously been demonstrated to show high activity at the mu-opioid receptor coupled with significantly less activity at the kappa-and delta-opioid receptors, each is pharmacologically relevant, and each has a distinct and unique structure. Although only effects on the endogenous ligand, b-endorphin, are likely to have a relevant evolutionary context, the use of additional ligands will help to better understand the nature and effects of the polymorphisms and offer relevance for the effects of these variations on commonly used animal models in biomedical science.
b-endorphin is a thirty one amino acid endogenous ligand derived from proopiomelanocortin. Although highly conserved across mammals, the peptides are not identical in primates (supplementary fig. S2 , Supplementary Material online). Although all Old and New World monkey species Sweeney et al. . doi:10.1093/molbev/msx105 MBE sequenced to date (including Macaca mulatta, Papio anubis, Chlorocebus sabaeus, Callithrix jacchus, Saimiri boliviensis, and others) are identical with a glutamine at the 31st position, all apes (including Homo sapiens, Pan troglodytes, Gorilla gorilla, Pongo abelii, and Nomascus leucogenys) are identical with a glutamate at the 31st position. Though these are not believed to be functionally important changes (Dores and Baron 2011) , each species' mu-opioid receptor was tested against its species' b-endorphin ( fig. 3, supplementary table S1 , Supplementary Material online). (The ape b-endorphin was tested against the rhesus mu opioid receptor and vice versa and, as expected, no differences in signaling were observed [data not shown]). Significant differences in cAMP response are observed across all polymorphisms studied except, surprisingly, the human A118G variant which has the greatest support in the literature. EC 50 values were significantly different in the rhesus macaque C77G polymorphism and the marmoset A111T polymorphism, but differences in the human C17T and squirrel monkey C55T polymorphisms appeared to be driven by changes in efficacy.
When various exogenous ligands are tested, different patterns of results are observed (supplementary table S1, Supplementary Material online). Fentanyl showed much less of an effect across species, with only the rhesus macaque C77G polymorphism showing a significant difference (fig. 4 , supplementary table S1, Supplementary Material online). As with b-endorphin, for the rhesus macaque polymorphism both the EC 50 and E max values differ significantly between the two variants. For all other species and variants, however, these values across polymorphisms, even if not necessarily across species, are not significantly different.
For morphine, the difference in efficacy is observed for both rhesus macaque C77G and squirrel monkey C55T, but this is coupled with significant changes in EC 50 values across all species except squirrel monkey ( fig. 5 , supplementary table S1, Supplementary Material online). It is for morphine that the most robust and consistent differences are observed. These differences also are in accordance with results suggested in the behavioral and in vivo literature for both human polymorphisms Crystal et al. 2012; Haerian and Haerian 2013; Hwang et al. 2014) . A similar pattern is seen for DAMGO ( fig. 6, supplementary table S1 , Supplementary Material online), with the exception that the difference observed between the human C17T variants is not significant.
The variation that is observed across ligands does give some pause, though it is perhaps not surprising upon greater reflection. If changes are driven by direct interactions between the polymorphic sites and the ligand then ligands of substantially different structure that may interact with the protein in subtly different ways may be expected to show different effects on signaling. Despite the biological variability, there are several factors that provide confidence in the results. First, across technical replicates, the same patterns are observed; this includes independent transfections of each proteincoding plasmid. Although differences in receptor expression are not anticipated, any that do exist would necessarily have been the result of the polymorphisms themselves. Second, while differences within polymorphisms exist across ligands, the overall direction of the effects is the same. That is to say, whichever variant shows greater potency (or efficacy in the case of rhesus macaque and squirrel monkey) consistently shows this directionality regardless of ligand. Together this gives confidence in the validity of the data despite the biological variation.
Moreover, the results of the signaling assays are broadly what would be expected following the evolutionary and statistical analysis if there was parallel balancing selection. Polymorphisms in each of the species show at least some functional effects. The most notable findings from an evolutionary perspective are from the endogenous ligand b-endorphin. The results from other ligands, though exogenous, also support the functional implications of the polymorphisms. DAMGO, a synthetic peptide, and fentanyl, a phenylpiperidine derivative, shows parallel, but stronger differences, relative to b-endorphin. Morphine, the most structurally distinct of the ligands, shows the strongest evidence for functional divergence between the polymorphisms, though this is almost certainly not the selective force. It is also perhaps worth noting that this difference between morphine and the peptidergic ligands has been previously identified in the context of ligand biased signaling (Thompson et al. 2015) , which also suggests a fundamentally different binding between ligand and receptor. Taken as a whole, these in vitro results suggest a functional relevance for each of the amino acid replacement polymorphisms identified.
Discussion
Genetic variation in the mu-opioid receptor follows a nonrandom distribution. Although the preponderance of the receptor is under strong negative selection and evolutionary constraint, the N-terminal region of the protein harbors common variation changing amino acids in nearly all of the primate populations surveyed. Moreover, upon functional interrogation each of these amino acid variants seems to affect downstream signaling. In sum, it appears that across primate species two functionally distinct populations of mu-opioid receptor functionality are being created and maintained.
Common polymorphism is uniquely identified in the N-terminal domain, and nowhere else, in six separate primate species and although this is statistically significant and unexpected from neutral theory, it remains possible that this reflects a reduced level of constraint unique to the N-terminal domain. This is unlikely for a number of reasons. First, divergence between species is not enriched in the N-terminal domain meaning that any relaxation of constraint would have needed to arise separately in the recent history of multiple species. Second, in both humans and rhesus macaques these polymorphisms have been associated with differences both in naturalistic behaviors as well as in response to exogenous compounds (Miller et al. 2004; Barr et al. 2007 Barr et al. , 2010 Vallender et al. 2010; Schwandt et al. 2011) . Third, previous studies have likewise identified in vitro functional effects for the polymorphisms in human and rhesus although with significant caveats . This leads lastly to the findings here, that functional effects on signaling Convergent Balancing Selection on the Mu-Opioid Receptor . doi:10.1093/molbev/msx105 MBE can be observed for the polymorphisms across all species tested.
The functional effects observed here, as well as those observed previously for human and rhesus macaques, are differentially observed across ligands. For some ligands in some species, the effects are absent or insignificant. This is not unexpected as previous work has shown ligand biased signaling differences for the mu opioid receptor   FIG. 3 . Effects of OPRM1 polymorphisms on b-endorphin-induced inhibition of cAMP formation. HEK cells transduced with an inducible CREresponsive firefly luciferase reporter and stably expressing the target mu-opioid receptors were treated with 1 mM forskolin and varying concentrations of b-endorphin. For human mu-opioid receptor, human b-endorphin was used while for rhesus macaque, marmoset, and squirrel monkey mu-opioid receptor the non-ape simian b-endorphin was uses. Concentration response functions showing effects of species-specific pairwise variation are shown. EC 50 and E max values are shown with significance calculated using an extra sum of squares F-test. Sweeney et al. . doi:10.1093/molbev/msx105 MBE (Thompson et al. 2015) and the patterns of ligand effects on polymorphism parallel ligand effects on signaling. It is perhaps notable that stronger effects are observed for morphine, particularly compared with peptidergic ligands, which may reflect physicochemical differences in ligand-receptor interactions.
It is notable that the present studies do not investigate the mechanism by which these polymorphisms exert their MBE influence. Although it may be most parsimonious to expect it is a result of direct binding effects between ligand and receptor, this is by no means certain, nor is it required for the findings here to be meaningful. Previous studies have suggested that the human A118G polymorphism may alter receptor availability either through a downregulation of mRNA expression (Zhang et al. 2005; Mague et al. 2009; Oertel et al. 2012) or through changes in post-translational Convergent Balancing Selection on the Mu-Opioid Receptor . doi:10.1093/molbev/msx105 MBE modification that affect internalization and receptor recycling (Kroslak et al. 2007; Huang et al. 2012; Williams et al. 2013 ). This research is ongoing, but these differences likely reflect at least some of the variability observed in second messenger signaling assays.
Regardless, it is all but certain that if in fact balancing selection has resulted in two classes of segregating mu opioid receptor alleles that selective pressures have been on endogenous ligand binding effects. It is tempting to speculate on what natural behaviors may have driven this; certainly, the opioidergic system has been involved in numerous physiological traits (Bodnar 2016) . Perhaps the most appealing hypothesis posits that through its effects on stress response via the hypothalamic-pituitary-adrenal axis (Wand et al. 2002; Miller et al. 2004; Hernandez-Avila et al. 2007; Schwandt et al. 2011; Ducat et al. 2013; Lovallo et al. 2015) , these polymorphisms effectively create highly and lowly reactive individual populations maintained by frequency-dependent selection. It remains as to why this should be common across primate species, further explorations of polymorphism in the mu opioid receptor across mammals will illuminate just how generalizable these findings are.
In addition to naturalistic studies of behavior, these results have important implications for biomedical animal models. Not only does this suggest that certain behavioral differences that are observed between individuals across primate species (including humans) are the result of discrete genetic differences, but more importantly that they also derive from a shared molecular basis. This further supports the translational validity of non-human primate studies and suggests parallel pharmacogenetic effects. More broadly, this demonstrates the importance of considering the functional equivalency of genetic variation whether when modeling across species or when comparing across populations within a species.
Much of the work surrounding this variation in humans is associated with clinically relevant but not necessarily pathogenic, qualities; the genetic differences are associated with alcohol or opiate addiction. Yet surely, this cannot reflect the underlying evolutionary pressure driving the variation. Rather, it is easy to assume that there is selection on sensitivity to natural reward or in response to natural stressors. These studies show that common, functionally equivalent, genetic variation has arisen independently across diverse primate species including humans. This variation is unlikely to have arisen by chance and rather represents the result of a shared evolutionary pressure.
Materials and Methods
Blood and DNA Venous blood was collected from living animals in EDTAvacutainer tubes, and DNA was extracted using the Flexigene Kit (Qiagen, Valencia, CA). Bloods were collected from animals of captive born colonies at the New England Primate Research Center during routine preventative health care. All animals were maintained in accordance with the guidelines of the Harvard Medical School Standing Committee on Animals and the Guide for Care and Use of Polymorphism Discovery and Genotyping DNA from each species (M. fascicularis of Mauritian origin, n ¼ 35; M. mulatta of Chinese origin, n ¼ 40; C. a. sabeus, n ¼ 7; C. jacchus, n ¼ 32; S. b. peruviensis, n ¼ 8; S. b. boliviensis, n ¼ 17), was PCR amplified using primers designed for exons 1-4 of OPRM1. PCR products were run on a 1.5% agarose gel, stained with ethidium bromide, and the resulting bands were purified with QIAquick Gel Extraction Kit (Qiagen, Valencia, CA) and sequenced at Functional Biosciences Inc. (Madison, WI). In Indian-origin rhesus, comprehensive polymorphism discovery was performed in 43 animals and 365 were further genotyped at OPRM1 C77G using FRET-based hybridization probe melting analysis performed on a LightCycler 2.0 (Roche Applied Science) using manufacturer protocols.
Evolutionary Analysis
A McDonald-Kreitman test (McDonald and Kreitman 1991), using a 2 Â 2 contingency table, compared fixed divergence and polymorphism at synonymous and non-synonymous sites. The whole of the gene was included, as well as a priori partitioning based on protein tertiary structure (the N-terminal region compared with the rest of the protein) and genomic structure (exon 1 compared with the remainder of the gene). Only polymorphisms observed at MAFs >5% were included. Significance was tested using a Fishers Exact test. The conservative, two-tailed, significance results are reported though deviations in both the N-terminal domain and the remainder of the protein are in the directions expected, an excess of non-synonymous polymorphic sites and synonymous polymorphic sites respectively. Log-linear analysis on a 2 Â 2 Â 2 contingency table was also implemented using SPSS.
Cloning
New World monkey clones, both marmoset and squirrel monkey, as well as rhesus macaque clones previously (Miller et al. 2004) , were derived from cDNA using a PCR based strategy. RNA was extracted using TRIzol (Life Technologies, Grand Island, NY) from frozen brain tissue obtained post-mortem from animals euthanized for unrelated reasons. RNA was reverse transcribed to cDNA using QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA) according to manufacturer's protocols. cDNA was PCR amplified using primers designed and tested to include the entirety of the coding region of OPRM1 (Forward: GTGGCAGCGGCGAAAGGAAG, Reverse: CAGAGAGGA AAGAGGTTGGATGAC). All reactions were completed in a final volume of 25 ml, containing 12.5 ml GoTaq Green Master Mix (Promega, Madison, WI), 10 pmol of each primer and 50 ng of cDNA template.
PCR products were run on a 1.5% agarose gel stained with ethidium bromide. Bands were excised and purified using Sweeney et al. . doi:10.1093/molbev/msx105 MBE QIAquick Gel Extraction Kit (Qiagen, Valencia, CA), and the purified PCR products were sequenced to confirm the OPRM1 sequence. They were then inserted into pcDNA3.1/ V5-His-TOPO vector (Life Technologies, Grand Island, NY). Site directed mutagenesis, using Quick-change Lightening Site Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) per manufacturers protocols, was utilized to generate a plasmid expressing the variant form of OPRM1 for each species.
Human A118G and rhesus C77G plasmids were previously generated (Miller et al. 2004) . A plasmid expressing the human T17 polymorphism was generated using the human A118 plasmid via site directed mutagenesis as described above.
Cell Line Generation HEK293 cells were transduced with an inducible CREresponsive firefly luciferase reporter to create a stable cell line to measure the activity of the cAMP/PKA pathway (QIAgen, Valencia, CA). This cell line was subsequently used as a basis for all transient transfections of various mu-opioid receptors. For each biological replicate, the CRE-reporting cell line was transiently transfected with each of the nine OPRM1 plasmids using Effectene Transfection Reagent (Qiagen, Valencia, CA). Control cell lines were also generated either with only the reporter, or with the reporter and an empty pcDNA3/1V5-HIS-TOPO vector. Expression for all vectors was confirmed using endpoint PCR and qPCR.
Signaling Assays
Cells, expressing each OPRM1 clone, were seeded at $5 Â 10 5 cells per well of a 12 well plate in DMEM containing 2% FBS (Life Technologies, Grand Island, NY). Cells were incubated overnight, and the next day were treated with varying concentrations of an OPRM1-specific agonist, either morphine (Sigma-Aldrich, St Louis, MO), human b-endorphin (American Peptide Co., Sunnyvale, CA), non-human primate b-endorphin (University of Alberta, Institute of Biomolecular Design, Edmonton, AB), fentanyl (Sigma-Aldrich, St Louis, MO), or DAMGO (BACHEM, Torrance, CA) and 1 mM forskolin (LC Laboratories, Woburn, MA). The forskolin/agonist mixture was left on the cells for $20 h. It was then removed, and the cells were lysed using Cell Culture Lysis 5x Reagent (Promega, Madison, WI), and 20 ml of lysate was transferred to a 96-well plate in quadruplicate for technical replication. Plates were put into a Victor X5 multimode plate reader (Perkin Elmer, Waltham, MA) set to dispense 30 ml of Luciferase Assay Substrate (Promega, Madison, WI) and to read the resulting luminescence. Each of these assays was conducted three to four times.
Signaling Data Analysis
Data were analyzed using Graphpad Prism (GraphPad Software, Inc., La Jolla, CA). For each biological replicate 0% effect was defined by luciferase expression with 1 mM forskolin. Concentrations of agonists were titrated until the minimum concentration tested did not significant differ from this baseline. At each concentration relative luciferase is plotted as a percentage of forskolin alone. The raw signal with forskolin alone in relative luciferase units was on the order of 10 6 while the background expression without forskolin was on the order of 10 2 . EC 50 is defined as the concentration at which 50% of maximal effect is observed and E max is defined as the maximal effect as a percent inhibition of forskolin alone.
Supplementary Material
Supplementary data are available at Molecular Biology and Evolution online.
